HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

506.075

0.000

Number of Gainers:7

Number of Losers:1

Number of Flat:25

PE:- -

High:506.075

Open:506.075

Low:506.075

Close:506.075

Volume:- -

Turnover:- -

Market Cap:327.52B

Float Cap:290.90B

Loading ...

China's Midday Market: Shanghai Composite Up 0.42%, ChiNext Rises 1.61% as Pharma and Computing Power Surge

Akeso's Ivonescimab Gets Third Indication Approval in China

MT Newswires Live

Medical Equipment Procurement Shows Sustained Monthly Recovery, Sector Valuations Poised for Rebound

Listing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO

Akeso Says NMPA Approves Ivonescimab for 1L Treatment of SQ-NSCLC

Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo

AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC

Akeso - Nmpa Approves Ivonescimab for 1L Treatment of Sq-Nsclc

THOMSON REUTERS

Akeso Says China NMPA Approves Ivonescimab Plus Chemo for First-Line Squamous NSCLC

Akeso - China Nmpa Approves Ivonescimab Plus Chemotherapy for First-Line Advanced Squamous Nsclc

THOMSON REUTERS

Three Emerging Export Sectors: How Many Does Nanjing Jiangbei New Area Command?

ACOTEC-B (06669) Warns of Mid-Year Net Loss Up to 80.9 Million Yuan, Reversing from Profit

Acotec Scientific Expects Net Loss of no More than RMB 80.9 Mln for HY

Acotec Scientific - Expects Net Loss of no More than Rmb80.9 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS

Acotec Scientific - Expected Hy Result Due to One-Off Impairment Loss and Provision

THOMSON REUTERS

Yiling Receives Notice for Clinical Trial Application of Its New Chemical Drug 'LB220-D08 Extended-Release Tablets'

Zhaoke Ophthalmology Signs Exclusive Distribution Deal with Pharmentum Biopharma for Epinastine Eye Drops in China

Zhaoke Ophthalmology - Enters Exclusive Distribution Agreement with Pharmentum Biopharma in China

THOMSON REUTERS

Zhaoke Ophthalmology - Agreement to Commercialize Epinastine Hydrochloride Eye Drops in China (Excluding Hong Kong, Macau and Taiwan)

THOMSON REUTERS

Alphamab Oncology Schedules Board Meeting to Review Interim Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK1574/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":506.0749,"timestamp":1787533406726,"preClose":506.0749,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Pre-opening","change":0,"latestTime":"08-24 09:03:26","open":506.0749,"high":506.0749,"low":506.0749,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"pbRate":4.109535,"peRate":-81.157718,"turnoverRate":0.005444,"increases":7,"decrements":1,"flats":25,"marketCap":327518828720,"floatMarketCap":290901365136},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":506.0749,"amplitude":0,"preClose":506.0749,"low":506.0749,"pbRate":"4.109535","latestPrice":506.0749,"volume":0,"delay":0,"open":506.0749,"prevYearClose":556.26263,"prevWeekClose":506.075,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":505.128,"twentyDayClose":497.839,"sixtyDayClose":520.536,"secType":"PLATE","market":"HK","turnoverRate":0.005444,"peRate":-81.157718,"marketCap":327518828720,"floatMarketCap":290901365136,"timestamp":1787533406748,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":1,"flat":25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1197662897","title":"China's Midday Market: Shanghai Composite Up 0.42%, ChiNext Rises 1.61% as Pharma and Computing Power Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1197662897","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197662897?lang=en_us&edition=fundamental","pubTime":"2026-08-13 11:59","pubTimestamp":1786593583,"startTime":"0","endTime":"0","summary":"China's three major stock indexes opened higher on August 13 and then fluctuated, with heavyweight stocks lifting the indices. However, declining stocks outnumbered advancing ones, highlighting a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["512880","159967","BK1574","399006","159982","09939","BK1161","000300.SH","000905.SH","510880","159938","399300","515890","510300","BK1515","512510","000001.SH","000688.SH","399001"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659049182","title":"Akeso's Ivonescimab Gets Third Indication Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2659049182","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659049182?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:36","pubTimestamp":1786588580,"startTime":"0","endTime":"0","summary":"Akeso  said ivonescimab has been approved in China for a third indication, according to a Wednesday filing with the Hong Kong Exchange.The approval covers the use of ivonescimab in combination with chemotherapy as a first-line treatment for patients with squamous non-small cell lung cancer .This marks the third major authorization for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024.The drug was previously approved in May 2024 for EGFR-mutated locally advanced or metastatic non-squamous NSCLC patients who progressed after EGFR TKI treatment, and in April 2025 as a first-line treatment for locally advanced or metastatic NSCLC with PD-L1-positive expression.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BPRC5H50.USD","LU1961090484.USD","LU0417516902.SGD","LU2488822045.USD","LU0348827113.USD","BK1574","IE00B543WZ88.USD","LU0417516571.SGD","LU0561508036.HKD","IE00B5MMRT66.SGD","LU2778985437.USD","LU0348825331.USD","LU2476274308.USD","LU0417516738.SGD","LU1794554557.SGD","BK1161","LU1720050803.USD","LU0348783233.USD","LU2399975544.HKD","LU0634319403.HKD","LU2476274720.SGD","LU0348766576.USD","LU0348735423.USD","LU0540923850.HKD","09926","LU0348784397.USD","KURE","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128373791","title":"Medical Equipment Procurement Shows Sustained Monthly Recovery, Sector Valuations Poised for Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1128373791","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128373791?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:18","pubTimestamp":1786576706,"startTime":"0","endTime":"0","summary":"GTHT has released a research report noting that the ongoing implementation of equipment renewal policies is expected to drive long-term increases in medical equipment procurement levels. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","AGNG","601211","GDOC","MDEV","LGHT","CZA","REVS","BK0184","BK1574","BK0012","RSPH","09996","LCO","BK0201","BK0183","159883","IEIH","HART","NIFE","BK1100","BK1147","MEDX","BK0276","LNGR","02611","PTH","BK1564","BK0028","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166586489","title":"Listing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1166586489","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166586489?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:35","pubTimestamp":1786574109,"startTime":"0","endTime":"0","summary":"The Hong Kong Stock Exchange disclosed on August 12 that Suzhou Zelgen Biopharmaceuticals Co., Ltd. (ticker: 688266.SH) has submitted a listing application to the main board, with CICC serving as the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","688266","BK1574","HEXmain","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659904569","title":"Akeso Says NMPA Approves Ivonescimab for 1L Treatment of SQ-NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2659904569","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659904569?lang=en_us&edition=fundamental","pubTime":"2026-08-13 01:47","pubTimestamp":1786556839,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Says NMPA Approves Ivonescimab For 1L Treatment Of SQ-NSCLCAug 12 (Reuters)-Akeso Inc9926.HK:NMPA APPROVES IVONESCIMAB FOR 1L TREATMENT OF SQ-NSCLCFurther company coverage:9926.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU0417516738.SGD","LU2399975544.HKD","LU0634319403.HKD","KURE","LU1961090484.USD","LU2476274720.SGD","LU2778985437.USD","LU0348825331.USD","LU0417516902.SGD","LU0540923850.HKD","LU0348783233.USD","LU0348767384.USD","LU0561508036.HKD","LU1794554557.SGD","BK1574","LU2476274308.USD","09926","IE00B5MMRT66.SGD","LU0348735423.USD","LU2488822045.USD","IE00BPRC5H50.USD","LU1720050803.USD","LU0417516571.SGD","IE00B543WZ88.USD","BK1161","LU0348766576.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908461","title":"Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908461","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908461?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:42","pubTimestamp":1786542133,"startTime":"0","endTime":"0","summary":"BUZZ-Summit gains after partner Akeso secures China nod for lung cancer combo** Shares of Summit TherapeuticsSMMT.Orise 3% to $15.58** Co says its partner Akeso9926.HKannounced the marketing authoriza","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N44913L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","LU1720050803.USD","LU2488822045.USD","LU0417516571.SGD","KURE","BK1161","LU0634319403.HKD","LU0417516738.SGD","LU1794554557.SGD","LU0348767384.USD","09926","LU0348825331.USD","SMMT","LU0348783233.USD","LU2399975544.HKD","IE00BPRC5H50.USD","LU0348735423.USD","LU0348827113.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0348784397.USD","IE00B5MMRT66.SGD","BK4139","LU0348766576.USD","LU2476274308.USD","LU0561508036.HKD","LU1961090484.USD","BK1574","LU0417516902.SGD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147433388","title":"AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1147433388","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147433388?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:11","pubTimestamp":1786540312,"startTime":"0","endTime":"0","summary":"AKESO (09926) has announced that its independently developed, globally first-in-class bispecific antibody, Ivonescimab (marketed as Yidaifang®), has received approval from the China National Medical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","IE00BPRC5H50.USD","BK1574","BK1161","09926","LU1169589451.USD","LU1961090484.USD","IPOS","LU0348784397.USD","IE00B543WZ88.USD","LU2476274308.USD","LU0348766576.USD","LU1720050803.USD","BK4023","PD","LU0540923850.HKD","LU0348783233.USD","LU1794554557.SGD","LU0417516738.SGD","LU0348735423.USD","LU2778985437.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","KURE","LU1169590202.USD","LU0348825331.USD","LU2476274720.SGD","LU2399975544.HKD","LU0348827113.USD","LU0348767384.USD","LU0417516571.SGD","LU0634319403.HKD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970884","title":"Akeso - Nmpa Approves Ivonescimab for 1L Treatment of Sq-Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970884?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:52","pubTimestamp":1786539149,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B5MMRT66.SGD","LU0540923850.HKD","IE00BPRC5H50.USD","BK1161","LU0348783233.USD","LU0348827113.USD","IE00B543WZ88.USD","LU0417516738.SGD","LU0348766576.USD","LU0348825331.USD","09926","LU1720050803.USD","LU0348784397.USD","LU0417516571.SGD","LU0634319403.HKD","LU2476274720.SGD","LU0348735423.USD","BK1574","LU2488822045.USD","LU2778985437.USD","LU2399975544.HKD","KURE","LU0348767384.USD","LU2476274308.USD","LU1961090484.USD","LU1794554557.SGD","LU0417516902.SGD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972050","title":"Akeso Says China NMPA Approves Ivonescimab Plus Chemo for First-Line Squamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972050","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972050?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:22","pubTimestamp":1786537330,"startTime":"0","endTime":"0","summary":"Akeso says China NMPA approves ivonescimab plus chemo for first-line squamous NSCLCChina’s NMPA cleared ivonescimab with chemotherapy for first-line advanced squamous non-small cell lung cancer.Phase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL7SlDKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU0348766576.USD","LU0348783233.USD","LU1961090484.USD","LU0561508036.HKD","LU2476274720.SGD","LU1720050803.USD","LU0348784397.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU2399975544.HKD","LU2778985437.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0417516738.SGD","BK1161","LU0348735423.USD","LU0348827113.USD","LU0417516571.SGD","BK1574","IE00B543WZ88.USD","LU1794554557.SGD","09926","LU0348825331.USD","LU0634319403.HKD","KURE","LU0348767384.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997273","title":"Akeso - China Nmpa Approves Ivonescimab Plus Chemotherapy for First-Line Advanced Squamous Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997273?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:18","pubTimestamp":1786537113,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN44916C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BPRC5H50.USD","BK1161","LU0540923850.HKD","LU0417516902.SGD","LU0417516571.SGD","LU0348784397.USD","LU2488822045.USD","LU0348783233.USD","LU0561508036.HKD","LU0348766576.USD","LU1961090484.USD","LU0348825331.USD","LU2476274720.SGD","LU0348827113.USD","LU1794554557.SGD","LU1720050803.USD","09926","LU0348767384.USD","LU0348735423.USD","LU0634319403.HKD","LU2778985437.USD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","IE00B543WZ88.USD","KURE","BK1574","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133654525","title":"Three Emerging Export Sectors: How Many Does Nanjing Jiangbei New Area Command?","url":"https://stock-news.laohu8.com/highlight/detail?id=1133654525","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133654525?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:32","pubTimestamp":1786534358,"startTime":"0","endTime":"0","summary":"A fresh term, \"new-new three sectors,\" has recently gained traction in trade discussions. You may be familiar with the \"old three sectors\"—apparel, furniture, and home appliances—and the \"new three...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOMP","CHAT","ROBO","AIFD","AIBU","LNGR","MEDX","06978","ARTY","BK1574","BK1161","PBOT","AGIX","QTOC","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132439598","title":"ACOTEC-B (06669) Warns of Mid-Year Net Loss Up to 80.9 Million Yuan, Reversing from Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1132439598","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132439598?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:28","pubTimestamp":1786530504,"startTime":"0","endTime":"0","summary":"ACOTEC-B (06669) has issued a profit warning, projecting a net loss of no more than 80.9 million yuan for the six months ending June 30, 2026. This marks a sharp reversal from the net profit of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06669","BK1587","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658237976","title":"Acotec Scientific Expects Net Loss of no More than RMB 80.9 Mln for HY","url":"https://stock-news.laohu8.com/highlight/detail?id=2658237976","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658237976?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:25","pubTimestamp":1786530330,"startTime":"0","endTime":"0","summary":"BRIEF-Acotec Scientific Expects Net Loss Of No More Than RMB 80.9 Mln For HYAug 12 -Acotec Scientific Holdings Ltd6669.HK:EXPECTS NET LOSS OF NO MORE THAN RMB80.9 MLN FOR SIX MONTHS ENDED JUNE 30, 2026EXPECTED HY RESULT DUE TO ONE-OFF IMPAIRMENT LOSS AND PROVISIONFurther company coverage:6669.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","06669","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997617","title":"Acotec Scientific - Expects Net Loss of no More than Rmb80.9 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997617?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:22","pubTimestamp":1786530160,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1574","06669","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658764859","title":"Acotec Scientific - Expected Hy Result Due to One-Off Impairment Loss and Provision","url":"https://stock-news.laohu8.com/highlight/detail?id=2658764859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658764859?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:22","pubTimestamp":1786530160,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490QA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1100","BK1587","BK1574","06669"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197098611","title":"Yiling Receives Notice for Clinical Trial Application of Its New Chemical Drug 'LB220-D08 Extended-Release Tablets'","url":"https://stock-news.laohu8.com/highlight/detail?id=1197098611","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197098611?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:08","pubTimestamp":1786525684,"startTime":"0","endTime":"0","summary":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd. (002603.SZ) has announced that it recently received the \"Acceptance Notice\" from the National Medical Products Administration (NMPA) for the drug named...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002603","BK0042","159992","BMED","BK0188","BK0097","LNGR","BK1161","BK0239","MDTX","IBBQ","BK1574","IBBJ","MEDX","06978","PSYK","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978528","title":"Zhaoke Ophthalmology Signs Exclusive Distribution Deal with Pharmentum Biopharma for Epinastine Eye Drops in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978528","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658978528?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:55","pubTimestamp":1786524908,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology signs exclusive distribution deal with Pharmentum Biopharma for epinastine eye drops in ChinaZhaoke Ophthalmology entered a five-year exclusive distribution and promotion deal wit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4MYV5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1574","BK1191","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978534","title":"Zhaoke Ophthalmology - Enters Exclusive Distribution Agreement with Pharmentum Biopharma in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978534","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658978534?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:54","pubTimestamp":1786524877,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490PQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06622","BK1191","BK1583","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658785379","title":"Zhaoke Ophthalmology - Agreement to Commercialize Epinastine Hydrochloride Eye Drops in China (Excluding Hong Kong, Macau and Taiwan)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658785379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658785379?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:54","pubTimestamp":1786524877,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490PQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06622","BK1191","BK1583","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658920308","title":"Alphamab Oncology Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658920308","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658920308?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:36","pubTimestamp":1786523777,"startTime":"0","endTime":"0","summary":"Alphamab Oncology schedules board meeting to review interim resultsAlphamab Oncology scheduled a board meeting for Aug. 27, 2026 to review interim results for the six months ended June 30, 2026.Discla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4YBHQZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":11,"totalSize":284,"code":"91000000","status":"200"}]}}